KEAP1 and cancer: We posit that the anti-cancer benefit derived from systemic triterpenoid treatment targeting TIME cells will outweigh the cancer cell survival advantage since the cancer cells will likely have already achieved maximal NRF2 pathway activation through genetic KEAP1 mutation.